<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3594">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060122</url>
  </required_header>
  <id_info>
    <org_study_id>C.2017.026</org_study_id>
    <nct_id>NCT03060122</nct_id>
  </id_info>
  <brief_title>Combined InterX and Alpha-Stim for Optimized Rehab After Immobilization (CES Alpha-Stim) and Non-invasive Interactive Neurostimulation (InterX) for Optimized Rehabilitation Following Extremity Immobilization</brief_title>
  <official_title>The Clinical Feasibility of Combining Cranial Electrotherapy Stimulation (CES Alpha-Stim) and Non-invasive Interactive Neurostimulation (InterX) for Optimized Rehabilitation Following Extremity Immobilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be aimed at assessing the feasibility of a dual-device treatment prior to a
      rehabilitation session for an orthopaedic injury requiring immobilization, and its impact on
      improving outcomes and decreasing the risk for development of neuropathic pain. We will
      evaluate the clinical feasibility and effectiveness of incorporating the Alpha-Stim and
      Inter-X treatment into a standard rehabilitation protocol to address risk factors associated
      with the development of neuropathic pain (i.e., pain, range of motion, and skin temperature)
      as well as its impact on reduced pain medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once patients provide consent and we have determined that they meet inclusion criteria the
      process will occur as follows:

        1. Patients will be administered baseline demographic and standard medical history
           questionnaires, including information about prescription medication use. In addition,
           patients will fill out baseline self-report outcomes and be administered the (LANSS)
           Pain Scale. Range of motion and temperature will also be assessed during the initial
           session. Some of these measurements are standard of care and would be filled out by the
           patient even if they were not participating in the study.

      Usual CARE The usual care aspect of this study is the delivery of the pain treatment (NIN
      and CES) as is commonly used at the Center for the Intrepid. The experimental aspect is the
      combined delivery of the treatment, and the use of sham treatment as a control. The
      treatment (NIN and CES) will be delivered in a pragmatic fashion, with treatment delivered
      in conjunction with rehab visits and lasting approximately 4-weeks total. Each session will
      last approximately 20-40 minutes long, and will most often be delivered in conjunction with
      their rehab visit (physical therapy or occupational therapy) that occurs anywhere from 1 to
      3 times each week.

      STRICTLY RESEARCH The experimental aspect of the study will be the comparison of combined
      treatment (NIN + CES), standard NIN with sham CES, to standard care alone. Before initiation
      of treatment patients will be randomized to either NIN + CES, NIN + Sham CES, or standard
      care only immediately after the immobilization device (cast, brace, etc) has been removed.
      Randomization with be performed with a random number gerator. All groups will continue with
      their own rehabilitation as indicated throughout the entire course of the study treatment,
      and beyond as indicated by their therapist. We will keep track of rehab appointments and
      visits, but not control for them.

      3. At the 1-month follow-up, all subjects will fill out the same self-report outcome
      measures from baseline, to include prescription pain medication and be administered the
      LANSS pain scale. Range of motion and temperature will also be assessed.

      4. At the 2 and 4-month follow-up the same assessments will again be administered. If the
      subject has completed formal therapy prior to the 2 and 4 month follow-up time points he or
      she will be asked to return to the clinic to complete these assessments. Patients may be
      contacted by telephone or email, if agreeable, to provide a reminder for the return
      appointment(s).

      5. Outcomes will be compared between the three groups at each time point (i.e., initial, one
      month, two months, four months).

      6. All patients will be followed out to 4 months.

      Although every attempt will be made to collect data at these specific times, due to the
      variability of patient and clinic schedules, the actual timing of collection may vary (+/- 1
      week) and some of the proposed measures may not be collected at all time points.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>4 months</time_frame>
    <description>An 11-point verbalize NRS will be used to assess the subject's upper or lower extremity pain the day of each assessment as well as during therapy sessions. The 0 to 10 NPS has been found to be valid and reliable in many patient populations including the musculoskeletal population[37] and has been recommended for inclusion in the core NIH Toolbox for use with adults[38].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>4 months</time_frame>
    <description>The temperature at three locations (different for upper and lower extremity) will be recorded with an infrared thermometer (Exergen DT-1001RS Infrared Dermal Thermometer with Remote Sensor, Exergen Corp, Watertown, Massachusetts) on both the involved and uninvolved extremities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion (ROM)</measure>
    <time_frame>4 months</time_frame>
    <description>Active and/or passive ROM of the involved joints will be assessed using an electronic goniometer, and the reference of &quot;normal&quot; will be the non-involved limb. A measurement will be taken, but also the result will be dichotomously categorized as within 95% of opposite side - YES or NO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication</measure>
    <time_frame>4 months</time_frame>
    <description>An 11-point verbalize NRS will be used to assess the subject's upper or lower extremity pain the day of each assessment as well as during therapy sessions. The 0 to 10 NPS has been found to be valid and reliable in many patient populations including the musculoskeletal population[37] and has been recommended for inclusion in the core NIH Toolbox for use with adults[38].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Rating of Change (GRC)</measure>
    <time_frame>4 months</time_frame>
    <description>The GRC, a self-report instrument, assesses subjective perception of the efficacy of a particular treatment and the significance of that change [39]. A 15-point Likert type scale ranging from 1 (very great deal worse) to 15 (a very great deal better) and a 6-point Likert type scale ranging from 1 (a tiny bit important) to 6 (a very great important) will be used. The GRC is used to determine the minimal clinically important differences and will be used in this study to assess the participants' perceived magnitude of changes following the 30 minute combined NIN/CES treatment and again after each physical therapy or occupational therapy session for range of motion and pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale</measure>
    <time_frame>4 months</time_frame>
    <description>The LANNS assessment helps identify whether or not a patient exhibits neuropathic pain. The instrument consists of five self-report and two clinician administered sensory function items that assess dynamic mechanical allodynia and altered pin-prick threshold (PPT). Weighted scores for the seven items are binary (yes or no) and summed, giving a total score between 0 and 24. In terms of diagnostic validity, during the validation study this assessment yielded a sensitivity of 85% and specificity of 80%[</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Patient Reported Outcomes Measurement Information Systems (PROMIS) 29</measure>
    <time_frame>4 months</time_frame>
    <description>Emotional The PROMIS 29, a self-reported measure, assesses health-related quality of life (HRQOL) in seven domains (physical function, anxiety, depression, fatigue, sleep disturbance, social role satisfaction, pain interference, pain intensity). The instrument utilizes a 7-day recall period and consists of eight questions on a Likert-type scale, ranging from 1 to 5 , except for the pain intensity scale, which ranges from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Functional Scale(LEFS)</measure>
    <time_frame>4 months</time_frame>
    <description>The LEFS, originally described by Binkley et al, provides global assessment of function related specifically to the lower extremities.[50] It is one self-report outcome measure that can capture adverse impact on function from multiple injuries or specific locations in the lower extremity. It consists of 20 questions total related to functional activities, each with a possible score ranging from 0 to 4, where 0 indicates that the activity cannot be performed at all and 4 indicates that the activity be performed with no limitations. The total maximum score is 80 points, indicating no limitations with any of the functional tasks. It has been shown to be valid, reliable, and responsive to change in various patient populations and in different body regions in the lower extremity (ankle, knee, and hip).[50-52]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Disabilities of the Arm, Shoulder, and Hand (Quick DASH</measure>
    <time_frame>4 months</time_frame>
    <description>The DASH is an 11-item self-report measure that assesses a subject's perceived ability to complete twenty-one upper extremity functional activities using a 5-point Likert scale. The cumulative Quick DASH score is scaled from 0 to 100, with higher scores indicating increased disability. The DASH is well tested and has been validated and found reliable in many different upper limb musculoskeletal disorders[45-48]. The Minimally Clinically Important Difference (MCID) for the Dash is 10.83 points, and for the QuickDash is 15.91 points.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Post Operative Upper and Lower Extremity Immobilization, Rehabilitation</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient's randomized to this arm will receive standard post operative/ post immobilization rehabilitation care without the use of NIN or CES.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIN (InterX) and CES (Alpha-Stim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.Intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level.
InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. It delivers high-amplitude, high-density stimulation through the use of a hand-held device or its remote probes.The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIN and sham CES</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>InterX Therapy, also a type of non-invasive electrical stimulation, has been developed specifically for the treatment of acute and chronic pain. While Alpha-Stim CES is delivered transcranially, InterX Therapy is delivered on the skin of the involved area. InterX Therapy delivers high-amplitude, high-density stimulation through the use of a hand-held device or its remote probes. The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area. The electrical current is controlled through a handheld device, with standard treatment sessions lasting approximately 20 minutes to 45 minutes.
The sham CES devices will be identical to the active device, except the ear clip electrodes will not emit electricity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIN (InterX) and CES (Alpha-Stim)</intervention_name>
    <description>The experimental aspect of the study will be the comparison of combined treatment (NIN + CES), standard NIN with sham CES, to standard care alone. Before initiation of treatment patients will be randomized to either NIN + CES, NIN + Sham CES, or standard care only immediately after the immobilization device (cast, brace, etc) has been removed. Randomization with be performed with a random number gerator. All groups will continue with their own rehabilitation as indicated throughout the entire course of the study treatment, and beyond as indicated by their therapist. We will keep track of rehab appointments and visits, but not control for them.</description>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_label>NIN (InterX) and CES (Alpha-Stim)</arm_group_label>
    <arm_group_label>NIN and sham CES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. An orthopaedic/musculoskeletal postoperative injury that required cast or splint
             immobilization of the joint(s) to be treated of â‰¥ 2 weeks and available for treatment
             and are coming in for physical or occupational therapy

          2. Between the age of 18 - 65 years

          3. Read and speak English well enough to provide informed consent and follow study
             instructions

        Exclusion Criteria:

          1. Active infection, open sores, or open incisions (or anything that would inhibit the
             application of the stim) in the affected extremity.

          2. Any contraindications to electrical stimulation including: any type of implanted
             demand type cardiac pacemakers, implanted defibrillators, or implanted functioning
             devices (i.e., insulin pump); active cancerous tissue or are undergoing chemotherapy;
             known pregnancy or breastfeeding or history of epilepsy or other seizures.

          3. History of inflammatory skin diseases (psoriasis, dermatitis, etc.).

          4. Contralateral extremity involvement resulting in less than normal range of motion,
             muscle strength, or daily pain greater than 1/10.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Keizer</investigator_full_name>
    <investigator_title>Pain Psychologist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
